uniQure (NASDAQ:QURE) Price Target Cut to $6.00

uniQure (NASDAQ:QURE) had its target price decreased by equities research analysts at Mizuho from $7.00 to $6.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Mizuho’s price target would suggest a potential upside of 24.48% from the company’s current price.

A number of other research analysts also recently issued reports on the company. HC Wainwright reduced their price target on uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, March 1st. The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and reduced their price target for the company from $63.00 to $8.00 in a report on Thursday, February 29th. StockNews.com upgraded uniQure to a “sell” rating in a report on Friday, March 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 target price on shares of uniQure in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.91.

uniQure Stock Up 2.1 %

QURE opened at $4.82 on Wednesday. The company has a market cap of $230.59 million, a P/E ratio of -0.74 and a beta of 0.98. The business’s 50-day moving average price is $5.03 and its 200-day moving average price is $5.89. The company has a current ratio of 8.85, a quick ratio of 8.68 and a debt-to-equity ratio of 0.49. uniQure has a 12 month low of $4.25 and a 12 month high of $22.48.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $3.20 million. On average, equities analysts expect that uniQure will post -4.49 EPS for the current year.

Insiders Place Their Bets

In other news, COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Matthew C. Kapusta sold 27,904 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the sale, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares in the company, valued at $554,110.21. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,265 shares of company stock worth $339,845. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James & Associates lifted its position in uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 58.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 3,664 shares in the last quarter. Headlands Technologies LLC bought a new position in uniQure in the 3rd quarter valued at approximately $31,000. Harbor Capital Advisors Inc. lifted its position in uniQure by 21.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 5,389 shares in the last quarter. Finally, Pale Fire Capital SE lifted its position in uniQure by 9.2% in the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after acquiring an additional 5,500 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.